17,18-EEQ analogs preserve mitochondrial function to protect stressed tissues
PrimaryOmeicos' core theory is that synthetic, metabolically stable analogs of omega-3 CYP epoxyeicosanoids such as 17,18-EEQ can activate endogenous cell-protective pathways that preserve mitochondrial function during inflammatory, hypoxic, or ischemic stress. For OMT-28, the expected causal chain is: omega-3 epoxyeicosanoid mimicry leads to maintenance of NAD+/NADH and ADP/ATP balance, improved respiratory control, reduced mitochondrial reactive oxygen species, and better survival or function of stressed cardiomyocytes and other metabolically vulnerable cells. Testable predictions include improved mitochondrial biomarkers in primary mitochondrial disease, preserved cardiomyocyte viability after hypoxia/reoxygenation, reduced mitochondrial ROS after injury, and improved tissue function after ischemia/reperfusion or inflammatory challenge.
Popperian evaluation
The premise is credible. 17,18-EEQ and related omega-3 epoxyeicosanoids are bioactive lipid mediators with reported cardiovascular, anti-inflammatory, and tissue-protective effects, and OMT-28 is framed as a metabolically stable mimic of that biology. The causal chain also hangs together: mitochondrial redox balance, ADP/ATP balance, respiratory control, and mitochondrial ROS are all plausible readouts for stressed cardiomyocytes and inflamed epithelial tissue. The weak point is receptor-level specificity. The theory names Gi, PI3K, PPARalpha, Sirt1, Sirt3, NF-kB suppression, and inflammasome limitation, which is biologically plausible but broad enough that the exact first target remains underdefined.
Supporting evidence: 17,18-EEQ and related omega-3 CYP epoxyeicosanoids are linked to cardiovascular, anti-inflammatory, and tissue-protective effects.; OMT-28 preserved NAD+/NADH, ADP/ATP, and respiratory control ratios in hypoxia/reoxygenation-injured cardiomyocytes.; OMT-28 maintained SIRT3 expression and inhibited mitochondrial dysfunction in LPS-induced lung injury.
Counter evidence: The theory depends on OMT-28 preserving enough functional similarity to endogenous epoxyeicosanoids, but the provided evidence does not pin down one primary receptor or binding target.; The signaling chain includes several pathways, which makes the premise plausible but mechanistically crowded.
The theory explains a real pattern across the supplied evidence: OMT-28 protects cardiomyocytes after hypoxia/reoxygenation, reduces mitochondrial ROS, improves post-injury myocardial function in perfused mouse hearts, and protects lung epithelium during LPS injury. A mitochondria-centered model ties those findings together better than a simple anti-inflammatory claim, because the same argument predicts NAD+/NADH, ADP/ATP, respiratory control, ROS, and tissue function. Still, it does not yet beat all alternatives. Anti-inflammatory signaling, barrier preservation, or inflammasome suppression could sit upstream, downstream, or beside mitochondrial preservation. We do not fully understand yet whether mitochondrial preservation is the driver or one protected node in a wider stress-response program.
Supporting evidence: In cultured cardiomyocytes, OMT-28 preserved viability and mitochondrial function after hypoxia/reoxygenation.; In hypoxia/reoxygenation-injured cardiomyocytes, OMT-28 blocked injury-induced mitochondrial reactive oxygen species production.; In isolated perfused mouse hearts, OMT-28 improved myocardial function recovery and limited NLRP3 inflammasome activation.; In LPS lung injury, OMT-28 improved survival, reduced inflammatory injury, preserved epithelial barrier markers, and inhibited mitochondrial dysfunction.
Counter evidence: The lung injury data also support an epithelial barrier and anti-inflammatory explanation.; The heart data include inflammasome limitation, so mitochondrial preservation may share causality with inflammatory control rather than explain it alone.; No human efficacy evidence for primary mitochondrial disease is provided.
The theory is testable and can fail cleanly. It predicts specific biochemical and functional changes: preserved NAD+/NADH, ADP/ATP, respiratory control, lower mitochondrial ROS, better cardiomyocyte survival after hypoxia/reoxygenation, improved tissue recovery after ischemia/reperfusion, and improved mitochondrial biomarkers in primary mitochondrial disease. A negative result across those readouts, especially with confirmed drug exposure, would hit the theory directly. The main limitation is that some pathway language is broad. If one pathway fails but another changes, the theory could drift unless the core mitochondrial endpoints are declared primary before testing.
Supporting evidence: The theory names measurable readouts: NAD+/NADH, ADP/ATP, respiratory control, mitochondrial ROS, SIRT1/SIRT3 activity or expression, inflammatory cytokines, and tissue function recovery.; It predicts preserved cardiomyocyte viability after hypoxia/reoxygenation injury.; It predicts reduced mitochondrial ROS after hypoxic, ischemic, or inflammatory injury.; It predicts improved mitochondrial biomarkers in primary mitochondrial disease or other impaired energetic states.
Counter evidence: The mechanism lists multiple signaling routes, which could make partial failures easy to reinterpret.; The primary mitochondrial disease prediction is still more speculative than the cardiomyocyte and inflammatory injury predictions.
Reasoning tree
Public endorsements
No public statement from Commerce Berlin in the provided evidence addresses Omeicos' theory about 17,18-EEQ analogs preserving mitochondrial function. The records describe Omeicos' science and list financing participants, but they do not attribute any endorsement, mention, or contradiction of this theory to Commerce Berlin.
No supplied quote or publication shows Freie Universit making a public statement about OMEICOS' 17,18-EEQ analog theory. The records describe company financing, pipeline, and trial plans, but they do not attribute any endorsement, mention, or contradiction of the theory to this person/entity.
Falck is publicly tied to OMEICOS as a scientific co-founder and as an expert who pioneered CYP eicosanoid chemistry, the scientific base behind OMEICOS' omega-3 epoxyeicosanoid analog program. That is a public association with the theory area, but the provided evidence does not show him explicitly endorsing the specific claim that 17,18-EEQ analogs preserve mitochondrial function through the stated NAD+/NADH, ATP, and ROS mechanisms.
Evidence publication IDs: b1801e19-44ea-4359-bf02-47c3d3985bcd, 24975373-d549-4393-9c35-bd07dc3c9399
The evidence shows Karen Uhlmann is a co-founder and operations/IP executive at OMEICOS, but it does not show any public statement from her about the 17,18-EEQ analog theory, mitochondrial protection, or OMT-28's proposed mechanism. On this dossier, she stays silent on the theory.
There is no public evidence here. No quotes, records, or publications link Markus Henrich to this theory, so the defensible call is silence rather than endorsement, mention, or contradiction.